Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 593-595

  Sathekge, Mike ^a  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BURKITT LYMPHOMA; CANCER SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; GENERALIZED LYMPHADENOPATHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LYMPHOMA; HIV REACTIVE ADENOPATHY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; LYMPHOMA; NONHUMAN; PET-CT SCANNER; QUANTITATIVE DIAGNOSIS; TUMOR DIFFERENTIATION; B CELL LYMPHOMA; DIAGNOSTIC USE; FEMALE; MALE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84897023663     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2701-2     Document Type: Editorial

References (13)

1. Mhlanga JC, Durand D, Tsai HL, et al. Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/s00259-013-2671-9.
2. Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging. 2005;32:749-56. (Pubitemid 41125416)
3. Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43:349-66.
4. Bain BJ. Lymphomas and reactive lymphoid lesions in HIV infection. Blood Rev. 1998;12:154-62. (Pubitemid 28434426)
5. Mortensen BK, Nielsen SD, Christensen CB, Helweg-Larsen J. Immune reconstitution syndrome presenting as probable AIDS-related lymphoma: a case report. AIDS Res Ther. 2011;8:1-4.
6. Murdoch DM, Venter WD, Van RA, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4:9-18.
7. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:s117-27. (Pubitemid 36735769)
8. Sonet A, Graux C, Nollevaux MC, Krug B, Bosly A, Vander Borght T. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol. 2007;86:9-15. (Pubitemid 46138312)
9. Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med. 2013;27:163-9.
10. Liu Y. Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. AIDS Res Treat. 2012;2012:764291.
11. Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640-7.
12. Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging. 2009;36:1176-84.
13. Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959-61. (Pubitemid 37159292)